BCEL Projected Dividend Yield
Cl A Com/Atreca Inc ( OTCBB : BCEL )Atreca is a clinical-stage biopharmaceutical company utilizing its platform primarily to discover and develop antibody-based immunotherapeutics to treat a range of solid tumor types. Co.'s primary product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Co. owns worldwide rights to ATRC-101. 20 YEAR PERFORMANCE RESULTS |
BCEL Dividend History Detail BCEL Dividend News BCEL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |